Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:administeredBy |
oral
|
| gptkbp:CASNumber |
1035270-39-3
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:hasMolecularFormula |
C26H26N6O
|
| https://www.w3.org/2000/01/rdf-schema#label |
AZD4547
|
| gptkbp:indication |
gptkb:cancer
solid tumors |
| gptkbp:inhibitedBy |
fibroblast growth factor receptor
|
| gptkbp:mechanismOfAction |
FGFR inhibitor
|
| gptkbp:molecularWeight |
438.53 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:synonym |
N-(3-(1H-Benzimidazol-5-yl)phenyl)-6-(6-methoxy-pyridin-3-yl)imidazo[1,2-b]pyridazin-2-amine
AZD-4547 |
| gptkbp:target |
gptkb:FGFR3
gptkb:FGFR1 gptkb:FGFR2 |
| gptkbp:bfsParent |
gptkb:FGFR1
|
| gptkbp:bfsLayer |
6
|